The analyses, performed on a commercial targeted NGS panel of 50 genes, evidenced that APC, TP53, KRAS, PI3KCa and KDR were most frequently mutated in our patients but, regardless the relevance of these alterations in CRC, the mutational state of these genes did not affect the prognostic value of TRF2/VEGF-A, strengthening their clinical relevance. This evidence concerns the gene TERF2 and colorectal carcinoma.